Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE (ABBV)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
Most relevant news about ABBVIE
07/17ABBVIE : Signs Humira Patent License with Mylan
DJ
07/17ABBVIE : Announces HUMIRA® (adalimumab) Patent License with Mylan
PR
07/16ABBVIE : Announces Submission of Supplemental New Drug Application to US FDA for..
AQ
07/13ABBVIE : Provides Update on Phase 3 Study of Ibrutinib in Blood Cancer Diffuse L..
AQ
07/13ICER panel votes against elagolix for endometriosis
AQ
07/12ABBVIE : to Host Second-Quarter 2018 Earnings Conference Call
AQ
07/12ABBVIE : Announces Submission of Supplemental New Drug Application to US FDA for..
PU
07/12ABBVIE : Ex-dividend day for
FA
07/11ABBVIE : Says Study of Imbruvica in Type of Lymphoma Didn't Meet Primary Endpoin..
DJ
07/11ABBVIE : Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Blood Can..
PR
07/10ABBVIE : to Host Second-Quarter 2018 Earnings Conference Call
PR
06/30ABBVIE : Court Rules Against AbbVie in FTC Antitrust Suit -- Update
DJ
06/30ABBVIE : Court Rules Against AbbVie in FTC Antitrust Suit
DJ
06/29ABBVIE : and Calico Announce Extension of Groundbreaking Collaboration
AQ
06/28ABBVIE : IMBRUVICA Supplemental New Drug Application Accepted for Review by U.S...
AQ
More most relevant news
All news about ABBVIE
07/193 Biotech Stocks to Watch This Quarter
AC
07/17ABBVIE : Signs Humira Patent License with Mylan
DJ
07/17ABBVIE : Announces HUMIRA® (adalimumab) Patent License with Mylan
PR
07/16ABBVIE : Announces Submission of Supplemental New Drug Application to US FDA for..
AQ
07/14ABBVIE : Announces Submission Of Supplemental New Drug Application To US FDA For..
AQ
07/13ABBVIE : Provides Update on Phase 3 Study of Ibrutinib in Blood Cancer Diffuse L..
AQ
07/13ICER panel votes against elagolix for endometriosis
AQ
07/12ABBVIE : Studies from AbbVie Update Current Data on Alzheimer Disease (Digital t..
AQ
07/12ABBVIE : to Host Second-Quarter 2018 Earnings Conference Call
AQ
07/12ABBVIE : Announces Submission of Supplemental New Drug Application to US FDA for..
PU
More news
Sector news : Specialty & Advanced Pharmaceuticals
07/19AMGEN : and Cedars-Sinai in Collaboration for 'Health-Care Quality'
DJ
07/19MERCK AND : to Limit Drug-Price Increases, Cut Some Prices
DJ
07/19MERCK AND : Announces Plan to Lower Prices of Some Drugs
DJ
07/19JOHNSON & JOHNSON : Women who sued J&J declare victory after $4.69 billion talc ..
RE
07/19Barclays Poaches Senior Health-Care Banker From Deutsche Bank
DJ
07/19Novartis, MorphoSys and Galapagos Shares Rise on News of Deal
DJ
More sector news : Specialty & Advanced Pharmaceuticals
Official Publications
04/271st quarter results 
01/27Annual results 
01/26Annual results 
01/26SEC Filing 8K 
2017SEC Filing 10K 
20173rd quarter results 
More official Publications
News from SeekingAlpha
07/19Jane's June Dividend Increases And Income - Retirement Accounts 
07/19Big Pharma in the red on ramped up pressure on drug prices 
07/19AbbVie down 5% on upcoming bearish reports from Citron Research 
07/19ABBVIE : Fundamental Disconnect 
07/18FDA committed to easing approval path for biosimilars 
07/18FDA OKs J&J's single tablet darunavir-based regimen for HIV-1 
Latest Tweets
07/19AbbVie isn't THAT bad  
07/19AbbVie isn't THAT bad
5
07/19? TODAY'S ACTIVE FLOW: $MSFT $AAPL $BAC $GE $MU $NFLX $IBM $BABA $TSLA $CMCSA..
4
07/19Merck joins the list of drug makers freezing or lowering prices, but these mo.. 
07/19RECAP 7/19 +Pos Comments: $AAPL $FTNT $CAT $NOAH $E $CMCSA $EBAY $BB $TSM -Ne..
1
More tweets
Qtime:235
Financials ($)
Sales 2018 32 939 M
EBIT 2018 14 434 M
Net income 2018 10 789 M
Debt 2018 29 248 M
Yield 2018 3,82%
P/E ratio 2018 13,67
P/E ratio 2019 12,19
EV / Sales 2018 5,48x
EV / Sales 2019 5,08x
Capitalization 151 B
Chart ABBVIE
Duration : Period :
AbbVie Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Technical analysis trends ABBVIE
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 113 $
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Azita Saleki-Gerhardt Senior Vice President-Operations
William J. Chase Chief Financial Officer & Executive Vice President
Michael E. Severino Chief Scientific Officer & Executive VP
Robert J. Alpern Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE-2.39%151 404
MERCK KGAA-4.74%12 859
KYOWA HAKKO KIRIN CO LTD-2.97%11 440
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD98.64%11 422
JAZZ PHARMACEUTICALS PLC30.75%10 586
CONVATEC GROUP-0.78%5 349